Logo
Maxx Devid
Macrolide Antibiotics Market In-Depth Expert Analysis including Trends, Share, Size and Forecast 2024 - 2031

Global Macrolide Antibiotics Market, By Drugs (Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin and Telithromycin), Route of Administration (Oral and Parenteral), Infection (Mycoplasma pneumoniae, Legionella sp., Bordetella pertussis, Symptomatic Cat-Scratch Disease, Bacillary angiomatosis, Peliosishepatis, Cerebral Toxoplasmosis and Uncomplicated Skin Infections), End User (Hospital, Dermatology Clinic, Clinic, Ambulatory Centre and Research Laboratories) – Industry Trends and Forecast to 2029

Global Macrolide Antibiotics Market Analysis and Size

Macrolide antibiotics are known to possess immunomodulatory and anti-inflammatory effects that are utilized for certain health conditions. The rise in the prevalence for infectious diseases is escalating the growth of macrolide antibiotics market.

Global Macrolide Antibiotics Market was valued at USD 55,287.85 million in 2021 and is expected to reach USD 146,979.68 million by 2029, registering a CAGR of 13.00% during the forecast period of 2022-2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Get a Sample PDF of report - https://www.databridgemark...

Global Macrolide Antibiotics Market Definition

Macrolides refer to a class of antibiotics that are derived from Saccharopolyspora erythraea, and inhibit protein synthesis in bacteria by binding to the 50S ribosomal element. These antibiotics are effective against gram positive bacteria and intracellular pathogens, such as Chlamydia and Mycoplasma and Legionella.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Drugs (Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin and Telithromycin), Route of Administration (Oral and Parenteral), Infection (Mycoplasma pneumoniae, Legionella sp., Bordetella pertussis, Symptomatic Cat-Scratch Disease, Bacillary angiomatosis, Peliosishepatis, Cerebral Toxoplasmosis and Uncomplicated Skin Infections), End User (Hospital, Dermatology Clinic, Clinic, Ambulatory Centre and Research Laboratories)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest
1 month ago

No replys yet!

It seems that this publication does not yet have any comments. In order to respond to this publication from Maxx Devid, click on at the bottom under it